Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology and Market Forecasts 2017-2023 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cutaneous Squamous Cell Carcinoma - Market Insights, Epidemiology and Market Forecast - 2023" drug pipelines to their offering.

The market size for Cutaneous Squamous Cell Carcinoma of 7MM is estimated to grow at a CAGR of 6.1% for the forecast period

Cutaneous Squamous Cell Carcinoma (cSCC)- Market Insights, Epidemiology and Market Forecast - 2023 - 7MM report provides an overview of the disease and global market size of the Cutaneous Squamous Cell Carcinoma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Cutaneous Squamous Cell Carcinoma from 2013-2023.

Cutaneous Squamous Cell Carcinoma is a keratinocytic or non-melanoma skin cancer. cSCC is considered the second most common human malignancy after basal cell carcinoma (BCC).Actinic keratosis is the premalignant precursor for cSCC and early treatment might reduce patient morbidity. Unlike almost all basal-cell carcinomas, cutaneous squamous cell carcinomas are associated with a substantial risk of metastasis. The prognosis is favorable and only 2-5% of SCC metastasize.

Key Topics Covered:

  1. Report Introduction
  2. Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview at a Glance
  3. 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) (2013-2023)
  4. Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for MM
  5. Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for MM in
  6. Introduction
  7. Signs and Symptoms
  8. Pathophysiology
  9. Sub-types of cSCC
  10. Risk Factors
  11. Staging of cSCC
  12. Diagnosis
  13. Epidemiology and Patient Population
  14. Total number of Incident cases - MM Countries - (2016 &3)
  15. Treatment Algorithm
  16. United States
  17. NCCN Guidelines
  18. Europe
  19. British Association of dermatology (BAD) Guidelines
  20. French Dermatology Recommendations Association (aRED)
  21. European Dermatology Forum
  22. London Cancer Skin Pathway Board
  23. National Cancer Institute
  24. Unmet Needs
  25. Marketed Drugs

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/p32wk5/cutaneous

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Skin Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Skin Cancer Drugs